Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update 03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences 12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index 12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares 12.09.20 Syndax Announces Pricing of Public Offering of Common Stock 12.07.20 Syndax Announces Proposed Public Offering of Common Stock 12.06.20 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD 11.30.20 Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts 11.11.20 Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference 11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting 11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
12.06.20 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD
11.30.20 Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts
11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting
11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update
